Abstract
Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.
| Original language | English (US) |
|---|---|
| Title of host publication | Transgenic Plants |
| Publisher | Academic Press Inc |
| Pages | 207-244 |
| Number of pages | 38 |
| DOIs | |
| State | Published - Jan 1 2018 |
Publication series
| Name | Advances in Botanical Research |
|---|---|
| Volume | 86 |
| ISSN (Print) | 0065-2296 |
Fingerprint
Keywords
- Flavivirus
- Monoclonal antibody
- Nicotiana benthamiana
- Plant expression system
- Plant-made biologics
- Plant-made pharmaceutical
- Therapeutic enzymes
- Transient expression
- Vaccine
- Virus-like particle
ASJC Scopus subject areas
- Plant Science
Cite this
Recombinant Therapeutic Molecules Produced in Plants. / Chen, Qiang.
Transgenic Plants. Academic Press Inc, 2018. p. 207-244 (Advances in Botanical Research; Vol. 86).Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Recombinant Therapeutic Molecules Produced in Plants
AU - Chen, Qiang
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.
AB - Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.
KW - Flavivirus
KW - Monoclonal antibody
KW - Nicotiana benthamiana
KW - Plant expression system
KW - Plant-made biologics
KW - Plant-made pharmaceutical
KW - Therapeutic enzymes
KW - Transient expression
KW - Vaccine
KW - Virus-like particle
UR - http://www.scopus.com/inward/record.url?scp=85043366363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043366363&partnerID=8YFLogxK
U2 - 10.1016/bs.abr.2017.11.006
DO - 10.1016/bs.abr.2017.11.006
M3 - Chapter
AN - SCOPUS:85043366363
T3 - Advances in Botanical Research
SP - 207
EP - 244
BT - Transgenic Plants
PB - Academic Press Inc
ER -